This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Spero's (SPRO) IND Accepted by FDA for Pulmonary Disease Drug
by Zacks Equity Research
The FDA accepts Spero's (SPRO) IND for SPR720 in development for the treatment of nontuberculous mycobacterial pulmonary disease.
Alnylam's Share Price Rises YTD on Pipeline Developments
by Zacks Equity Research
Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.
ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio
by Zacks Equity Research
ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chronic pain.
Bristol Myers' Idhifa Fails to Meet Goal in Leukemia Study
by Zacks Equity Research
Bristol Myers' (BMY) phase III study evaluating Idhifa in patients with relapsed or refractory acute myeloid leukemia fails to meet the primary endpoint.
Horizon Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Horizon Therapeutics.
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
Editas' SCD Candidate Gets FDA's Rare Pediatric Disease Tag
by Zacks Equity Research
The FDA bestows a Rare Pediatric Disease designation on Editas' (EDIT) experimental candidate EDIT-301, which is being developed for treating sickle cell disease.
Bristol Myers to Buy Forbius to Boost Immunotherapy Pipeline
by Zacks Equity Research
Bristol Myers (BMY) enters into an agreement to acquire privately-held Forbius in a bid to boost its pipeline of immunotherapies.
Vertex's Triple Combo Cystic Fibrosis Pill Kaftrio Gets EU Nod
by Zacks Equity Research
Vertex's (VRTX) triple combo regimen Kaftrio (ivacaftor/tezacaftor/elexacaftor) secures a nod in Europe to treat the younger lot aged 12 years and above with cystic fibrosis.
5 Biotech Stocks Up More Than 100% This Year So Far
by Zacks Equity Research
Here we discuss five biotech companies recording impressive growth so far in 2020.
5 Reasons to Invest in Horizon Therapeutics Amid Coronavirus
by Zacks Equity Research
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. The company's efforts to develop its pipeline are impressive.
BioNTech (BNTX) Looks Good: Stock Adds 10.2% in Session
by Zacks Equity Research
BioNTech (BNTX) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Axsome's NDA Filing for Migraine Candidate in Q4 on Track
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-07, which is developed as an acute treatment of migraine. The company is on course to file the NDA in Q4.
Sorrento to Buy Privately-Held SmartPharm to Boost Pipeline
by Zacks Equity Research
Sorrento (SRNE) signs agreement to acquire SmartPharm Therapeutics in exchange for its common stock worth up to $19.4 million.
BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism
by Zacks Equity Research
BioMarin's (BMRN) BLA for vosoritide is based on final data from a phase III study, long-term data from the ongoing phase II and phase III extension studies and extensive natural history data.
Pluristem Completes Enrollment in Phase I Hematology Study
by Zacks Equity Research
Pluristem (PSTI) completes enrollment in the phase I study in patients with complete hematopoietic recovery following hematopoietic cell transplantation in the United States and Israel.
Alkermes Starts Phase II Study on ALKS 4230 for Solid Tumors
by Zacks Equity Research
Alkermes (ALKS) initiates phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.
Albireo Down on Unimpressive Data From Mid-Stage NASH Study
by Zacks Equity Research
Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.
CorMedix (CRMD) Jumps: Stock Rises 9.8%
by Zacks Equity Research
CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Bristol Myers & Dragonfly Team Up for Immunotherapy Program
by Zacks Equity Research
Bristol Myers (BMY) collaborates with Dragonfly Therapeutics, Inc. for its experimental immunotherapy program.
Unity Shares Slump 66% As Lead Arthritis Drug Fails in Study
by Zacks Equity Research
Unity's (UBX) lead pipeline candidate, UBX0101, fails to meet primary endpoint in a phase II study in patients with moderate-to-severe painful osteoarthritis of the knee.
Encompass Health's Buyout Spree on Track, PPE Costs High
by Zacks Equity Research
Encompass Health (EHC) continues to benefit from buyouts and cash generating abilities. However, increased PPE utilization is worrisome.
Mesoblast Gets Favorable Votes From FDA Committee for Ryoncil
by Zacks Equity Research
Mesoblast (MESO) gets ODAC's vote in the ratio of 9:1 for GVHD drug.
BioMarin's MAA for Dwarfism Candidate Gets EMA Validation
by Zacks Equity Research
The EMA sanctions BioMarin's (BMRN) marketing authorization application for vosoritide to treat children with achondroplasia, the most common type of dwarfism.
Novo Nordisk (NVO) Resumes Phase III Hemophilia Studies
by Zacks Equity Research
Novo Nordisk (NVO) resumes the phase III studies on concizumabin in hemophilia A and B patients regardless of inhibitor status.